1. Home
  2. TRVG vs PRTA Comparison

TRVG vs PRTA Comparison

Compare TRVG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo trivago N.V.

TRVG

trivago N.V.

HOLD

Current Price

$5.87

Market Cap

422.6M

Sector

Technology

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.57

Market Cap

449.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVG
PRTA
Founded
2005
2012
Country
Germany
Ireland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
422.6M
449.7M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
TRVG
PRTA
Price
$5.87
$9.57
Analyst Decision
Hold
Buy
Analyst Count
6
9
Target Price
$3.95
$19.00
AVG Volume (30 Days)
163.9K
333.2K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
N/A
$814,000.00
Revenue This Year
$15.59
$1,111.38
Revenue Next Year
$8.42
N/A
P/E Ratio
$16.98
$37.50
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$7.73
52 Week High
$6.49
$11.80

Technical Indicators

Market Signals
Indicator
TRVG
PRTA
Relative Strength Index (RSI) 56.87 57.94
Support Level $2.76 $8.10
Resistance Level N/A $10.11
Average True Range (ATR) 0.42 0.36
MACD 0.06 0.04
Stochastic Oscillator 69.27 75.43

Price Performance

Historical Comparison
TRVG
PRTA

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: